KCIA
CRBP icon

Kingsbury Capital Investment Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$6K Buy
+1,123
New +$7.92K 0.01% 77
2022
Q2 		– Sell
-1,127
Closed -$18K – 98
2022
Q1 		$18K Buy
+1,127
New +$14.9K 0.02% 96

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kingsbury Capital Investment Advisors's CRBP Position: Q3 2022 in Review

Kingsbury Capital Investment Advisors opened a new position in Corbus Pharmaceuticals (CRBP) in Q3 2022: 1,123 shares worth $6K. The stake represents 0.01% of the portfolio and ranks #77 among its holdings. This is a return to the name: Kingsbury Capital Investment Advisors previously reported a position in CRBP as recently as Q1 2022.

Kingsbury Capital Investment Advisors first reported a position in CRBP in Q1 2022 and has held it in 2 quarters since. The position peaked at $18K in Q1 2022. 64 funds tracked by Wall St. Rank hold CRBP as of Q3 2022.

  • Kingsbury Capital Investment Advisors held 1,123 shares of Corbus Pharmaceuticals worth $6K as of Q3 2022.
  • Corbus Pharmaceuticals was a new Kingsbury Capital Investment Advisors position in Q3 2022.
  • Corbus Pharmaceuticals made up 0.01% of Kingsbury Capital Investment Advisors's portfolio in Q3 2022, its #77 holding.
  • Kingsbury Capital Investment Advisors first reported a position in Corbus Pharmaceuticals in Q1 2022 and has held it in 2 quarters since.
  • Kingsbury Capital Investment Advisors's Corbus Pharmaceuticals position peaked at $18K in Q1 2022.
  • 64 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2022.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.